CC-91516

CC-91516: sourced facts only. name: "CC-91516 (also called CC0776314), a selective and potent inhibitor of ERK1/2 and NLK, was discovered via a phenotypic screen of a kinase-focused library for compounds that synergize with mTOR kinase inhibitor CC-223 to induce apoptosis in combination with CC-223." [DOI:10.1158/1538-7445.am2022-1180]; target: "CC-91516 (also called CC0776314), a selective and potent inhibitor of ERK1/2 and NLK, was discovered via a phenotypic screen of a kinase-focused library for compounds that synergize with mTOR kinase inhibitor CC-223 to induce apoptosis in combination with CC-223." [DOI:10.1158/1538-7445.am2022-1180]; target: "CC-91516 (also called CC0776314), a selective and potent inhibitor of ERK1/2 and NLK, was discovered via a phenotypic screen of a kinase-focused library for compounds that synergize with mTOR kinase inhibitor CC-223 to induce apoptosis in combination with CC-223." [DOI:10.1158/1538-7445.am2022-1180]; developer: "1Bristol Myers Squibb, San Diego, CA." [DOI:10.1158/1538-7445.am2022-1180]; stage: "CC-91516 has good oral bioavailability and shows excellent anti-tumor activity in vivo against both BRAF and CTNNB1 mutant xenograft models." [DOI:10.1158/1538-7445.am2022-1180]